Order intake up 49% organically, but EBIT 29% below ABGSCe Less able to scale as costs increase; we ...
Fair value range of SEK 9-18 (9-21) Q4e: strong Freemelt ONE sales and an insurance one-off For Q4e,...
En rapport i linje med våra förväntninga Diamyds rapport för det första kvartalet i det brutna räken...
Efterfrågan är gynnsam på samtliga marknader utom Kina Den organiska tillväxten i orderingången var ...
Redeye is favorable to the news that Paxman has received its EU Medical Device Regulation certificat...
VEF took a defensive stance in 2022, focusing on strengthening its balance sheet and reprioritising ...
The most important aspects are organic growth and gross margins in our view.
The strong finish to 2022 was clearly overshadowed by a disappointing 2023 EBITDA margin guidance, ...
CapMan will report its Q4 on 2 February. We expect solid underlying performance, while a quiet trans...
Beijer Group reported an order intake of about SEK603m and sales of close to SEK589m, translating in...
Fortsatt god marknad, marginalerna fortsatte expandera Efterfrågan var generellt god under kvartalet...
Preliminary Q4 sales in line with ABGSCe, EBIT slightly above CEO Christian Sundin leaves after 16 y...
Redeye comments on the first deliveries of the new Carbonhand to patients and is happy to see a good...
Redeye endorses the news that Egetis Therapeutics has conducted a directed share issue of SEK210m an...
Redeye shares its preview of Sedana Medical’s Q4 2022 results, due on February 16.
Redeye shares its preview of BONESUPPORT’s Q4 2022e results and anticipates another record quarter.
Dags för Q4’22-rapport Vi förväntar oss en siffermässigt relativt odramatisk rapport för Q4’22 den 2...
Redeye states its view on today’s December ARR update from Hoylu that closing its Q4 2022 figures.
The upgrade implies Q4 was a lot better than we previously estimated but also suggests further impro...
Mangold Insight initiate coverage of the biotechnology company Biosergen with a buy recommendation a...
